Dialysis company shares plunge after Ozempic trial success vs. kidney trouble

The trial success of Novo Nordisk's hit drug against kidney failure sent shares of a German kidney dialysis services firm plummeting on Wednesday.

Related Keywords

Germany ,German , ,Novo Nordisk ,Fresenius Medical Care ,Medical Care ,Article Normal ,Pharmaceuticals ,Machinery ,Agricultural Machinery ,Printing Publishing ,Healthcare Life Sciences ,Aerospace Defense ,Defense Equipment Products ,Industrial Goods ,Media Entertainment ,Financial Performance ,Share Price Movement Disruptions ,New Products Services ,Research Development ,Corporate Industrial News ,Products Services ,New Product Service Testing ,Political General News ,Dialysis ,Diabetes ,Health ,Medical Conditions ,Medical Treatments Procedures ,Content Types ,Factiva Filters ,C Amp Ampe Exclusion Filter ,C Amp Ampe Industry News Filter ,Fresenius Medical Care Ag Amp Co Kgaa ,Xe Fme ,Fresenius Medical Care Ag Amp Co Kgaa Adr ,Fms ,Fresenius Se Amp Co Kgaa ,Xe Fre ,Novo Nordiska S ,Dk Novo B ,Davita Inc ,Dva ,Novo Nordiskas Adr ,Nvo ,Share Price Movement ,Disruptions ,New Products ,Services ,Research ,Development ,Corporate ,Industrial News ,Products ,New Product ,Service Testing ,Political ,General News ,Medical Treatments ,Procedures ,Printing ,Publishing ,Healthcare ,Life Sciences ,Aerospace ,Defense ,Defense Equipment ,Media ,Entertainment ,